While no ongoing trials utilize rintatolimod as a monotherapy, the drug’s safety and optimal dosage as an adjuvant for a HER-2/neu peptide vaccine is being evaluated in a randomized phase I/II breast cancer trial (NCT01355393). The gene discussed is ERBB2; the disease is breast carcinoma.